Immutep To Present New Data From EFTISARC-NEO Phase II Evaluating Novel Triple Combination Including Efti In Soft Tissue Sarcoma

Author: Benzinga Newsdesk | September 18, 2024 08:09am

• Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual Meeting
• EFTISARC-NEO is the first trial to evaluate efti in a neoadjuvant (prior to surgery) setting
• Soft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical need
  
  
  
   

SYDNEY, AUSTRALIA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) for patients with  soft tissue  sarcoma (STS), will be presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting taking place 13-16 November 2024, in San Diego, California. 

Posted In: IMMP